After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...